Compare RVI & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVI | ZVRA |
|---|---|---|
| Founded | N/A | 2006 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 778.2M | 689.4M |
| IPO Year | 2025 | 2015 |
| Metric | RVI | ZVRA |
|---|---|---|
| Price | $25.65 | $10.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 128.6K | ★ 871.3K |
| Earning Date | N/A | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.74 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $43.97 |
| Revenue Next Year | N/A | $15.93 |
| P/E Ratio | ★ N/A | $13.82 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $22.21 | $8.01 |
| 52 Week High | $77.39 | $15.04 |
| Indicator | RVI | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 38.24 |
| Support Level | $24.29 | $10.07 |
| Resistance Level | $29.49 | $11.07 |
| Average True Range (ATR) | 0.86 | 0.52 |
| MACD | -0.21 | -0.05 |
| Stochastic Oscillator | 33.04 | 25.08 |
Robinhood Ventures Fund I is a closed-end investment company. The investment objective, the Fund will mainly invest, under normal circumstances, in a concentrated portfolio generally consisting of ten or more private companies that, in the view, are growing companies at the frontiers of their respective sectors and industries. The Fund operates as a single segment.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.